United Therapeutics (UTHR) director sells 200 shares under 10b5-1 plan

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On March 16, 2026, she sold 200 shares of Common Stock at an average price of $535.44 per share in a sale classified as an open-market transaction.

After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		200	D	$535.44	4,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 24, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) disclose for Judy D. Olian?

Judy D. Olian reported selling 200 shares of UNITED THERAPEUTICS common stock. The transaction occurred on March 16, 2026, as an open-market sale at an average price of $535.44 per share, according to a Form 4 insider filing.

At what price did Judy D. Olian sell UNITED THERAPEUTICS (UTHR) shares?

She sold the shares at an average price of $535.44 each. The Form 4 specifies this per-share price for the 200 shares of common stock sold in an open-market transaction on March 16, 2026, by the UNITED THERAPEUTICS director.

How many UNITED THERAPEUTICS (UTHR) shares does Judy D. Olian hold after the sale?

After the reported sale, she directly holds 4,445 shares. The Form 4 shows this as her post-transaction direct ownership in UNITED THERAPEUTICS common stock, following the 200-share open-market sale on March 16, 2026.

Was Judy D. Olian’s UNITED THERAPEUTICS (UTHR) stock sale under a 10b5-1 plan?

Yes, the sale was made under a pre-arranged Rule 10b5-1 trading plan. A footnote states the transaction followed a plan she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than initiated opportunistically.

What role does Judy D. Olian hold at UNITED THERAPEUTICS (UTHR)?

Judy D. Olian is identified as a director of UNITED THERAPEUTICS. The Form 4 filing lists her as a reporting person with director status, providing context that the transaction reflects activity by a member of the company’s board of directors.

Did the UNITED THERAPEUTICS (UTHR) Form 4 report any option exercises or derivatives for Judy D. Olian?

No derivative transactions or option exercises are reported in this Form 4. The filing only shows a non-derivative open-market sale of 200 shares of common stock and lists no remaining derivative positions in the derivative summary.